Sclareol is reported to inhibit cell proliferation and sensitize cells to bortezomib through increasing the expression of Cav-1 and down-regulating superoxide dismutase1 (SOD1) protein level in cervical cancer cells (Zhang et al., 2017b). The gene discussed is CAV1; the disease is cervical carcinoma.